23.12.2020 12:21:19
|
3B BlackBio To Use OraSure OMNIgene·ORAL Collection Device For SARS-CoV-2 Test
(RTTNews) - OraSure Technologies, Inc. (OSUR) and microbiome laboratory and analytical services announced that its OMNIgene·ORAL collection device was included in the FDA Emergency Use Authorization amendment granted to 3B BlackBio Biotech, a supplier and developer for RT-PCR diagnostic assays in India. The EUA amendment will allow 3B BlackBio Biotech's North American distributor, Genophyll Enterprises, to expand saliva COVID-19 PCR-based viral diagnostic testing across the U.S. as well as from their upcoming New Jersey-based laboratory.
OraSure's OMNIgene·ORAL saliva collection devices are intended for use by individuals to collect and immediately stabilize saliva specimens suspected of containing SARS-CoV-2 ribonucleic acid at ambient temperature for transport.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu OraSure Technologies Inc.mehr Nachrichten
Analysen zu OraSure Technologies Inc.mehr Analysen
Aktien in diesem Artikel
OraSure Technologies Inc. | 3,60 | 0,00% |